Safety, tolerability, pharmacokinetics, and efficacy of single inhaled administrations of trospium chloride inhalation powder (TrIP) in patients with chronic obstructive pulmonary disease.

Trial Profile

Safety, tolerability, pharmacokinetics, and efficacy of single inhaled administrations of trospium chloride inhalation powder (TrIP) in patients with chronic obstructive pulmonary disease.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 15 Jul 2011

At a glance

  • Drugs Trospium chloride (Primary)
  • Indications Chronic obstructive pulmonary disease
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 15 Jul 2011 Actual end date (Jun 2007) added as reported by ClinicalTrials.gov.
    • 27 Sep 2007 Positive interim results have been announced by Alkermes and Indevus.
    • 10 Jul 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top